共 35 条
- [1] [Anonymous], SCEMBL ASC TABL OR U
- [2] [Anonymous], 2022, NOV SCEMBL NOV MECH
- [3] [Anonymous], PHARM STUD ASC SUBJ
- [4] How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA) [J]. CANCER MEDICINE, 2020, 9 (12): : 4160 - 4165
- [5] Cortes J., 2019, HEMASPHERE, V3, P397, DOI DOI 10.1097/01.HS9.0000561812.22500.D8